IPO Issue Details
Issue Price / Price Band₹140 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size107 Shares per Lot
Total Issue Size2,92,89,367 shares (aggregating up to ₹410.05 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh Capital-cum-Offer for Sale
Exchange / PlatformNSE & BSE
IPO TypeMainboard
Subscription OpenMon, 06 Jan 2025
Subscription CloseWed, 08 Jan 2025
Anchor AllotmentSun, 05 Jan 2025
Basis of AllotmentThu, 09 Jan 2025
Initiation of RefundsFri, 10 Jan 2025
Credit of Shares to DematFri, 10 Jan 2025
Listing DateMon, 13 Jan 2025
UPI Mandate Deadline2025-01-08
Application & Investment Details
Retail — Min (1 Lots)14980 — 107 shares
Retail — Max (13 Lots)₹194,740 (13 Lots)
HNI — Min (14 Lots)209720 — 1498 shares
EPS (Pre-IPO)₹3.25
EPS (Post-IPO)₹3.64
P/E Ratio (Pre-IPO)43.04x
P/E Ratio (Post-IPO)38.5x
Pre-IPO Promoter Holding18,44,91,662 shares
Post-IPO Promoter Holding19,94,91,662 shares
Fresh Issue Shares1,50,00,000 shares (aggregating up to ₹210.00 Cr)
Offer for Sale Shares1,42,89,367 shares of ₹10 (aggregating up to ₹200.05 Cr)
About Standard Glass Lining Technology Ltd
Incorporated in September 2012, Standard Glass Lining Technology Limited is a manufacturer of engineering equipment for the pharmaceutical and chemical sectors in India. The company has the capability to manage the entire production process in-house.The company provides turnkey solutions, including design, engineering, manufacturing, assembly, installation, and standard operating procedures for pharmaceutical and chemical manufacturers.The company's product product portfolio includesReaction Systems;Storage, Separation and Drying Systems; andPlant, Engineering and ServicesThe company manufactures specialized engineering equipment using glass-lined materials, stainless steel, and nickel alloy.The company's customer includes Apitoria Pharma Private Limited, Aurobindo Pharma Limited, CCL Food and Beverages Private Limited, Cohance Lifesciences Limited, Cadila Pharmaceutical Limited, Deccan Fine Chemicals (India) Private Limited, Dasami Lab Private Limited, Laurus Labs Limited, Granules India Limited, Macleods Pharmaceuticals Limited, MSN Laboratories Private Limited, Natco Pharma Limited, Honour Lab Limited, Hetero Drugs Limited, Hetero Labs Limited, Hazelo Lab Private Limited, Piramal Pharma Limited, Sanvira Biosciences Private Limited, Suven Pharmaceuticals Limited, Tagros Chemicals India Private Limited, Vamsi Labs Limited and Viyash Life Sciences Private Limited.The company has eight manufacturing units situated in Hyderabad, Telangana.The company's sales offices are situated in Vadodara, Gujarat, Ankleshwar, Gujarat, Mumbai, Maharashtra and Vishakhapatnam, Andhra Pradesh and sales team members are in Jhagadia, Gujarat, Chennai, Tamil Nadu, New Delhi, Bengaluru, Karnataka and Vijayawada, Andhra Pradesh with pan-India reach.As of September 30, 2024, the company had 460 full-time employees and 731 contract labourers.Competitive StrengthSpecialised engineering equipment manufacturers for the pharmaceutical and chemical sectors.Customized and innovative range of products throughout the entire pharmaceutical and chemical manufacturing value chain.Strategically located manufacturing facilities with advanced technological capabilities.Long term relationships with marquee clientele across sectors.Consistent track record of profitable growth.
Objects of the Issue
(Standard — DRHP pending)
Standard Glass Lining Technology Ltd proposes to utilise the net proceeds from the Issue for the following objects:
1
Funding of Capital Expenditure Requirements
2
Working Capital Requirements
3
General Corporate Purposes
Detailed fund allocation will be available once the company files DRHP with
SEBI.
Shareholding & Lock-in
Pre-IPO Promoter Holding
18,44,91,662 shares
Post-IPO Promoter Holding
19,94,91,662 shares